142 related articles for article (PubMed ID: 34246179)
21. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
22. An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.
Abravanel DL; Nishino M; Sholl LM; Ambrogio C; Awad MM
J Thorac Oncol; 2018 Aug; 13(8):e131-e133. PubMed ID: 29631033
[No Abstract] [Full Text] [Related]
23. Sclerosing pneumocytoma: Case report of a rare endobronchial presentation.
Khanna A; Alshabani K; Mukhopadhyay S; Lam L; Ghosh S
Medicine (Baltimore); 2019 Apr; 98(15):e15038. PubMed ID: 30985653
[TBL] [Abstract][Full Text] [Related]
24. Pulmonary sclerosing pneumocytoma mimicking carcinoid on preoperative imaging in a 14-year-old female.
Mandal A; Kumar S; Chhebbi M; Nandi S; Arunraj ST; Agarwal S
Indian J Thorac Cardiovasc Surg; 2021 Nov; 37(6):676-679. PubMed ID: 34776665
[TBL] [Abstract][Full Text] [Related]
25. Concomitance of pulmonary spindle cell carcinoma and sclerosing pneumocytoma in a woman: A case report.
LuLu X; Jian S
Medicine (Baltimore); 2019 Dec; 98(51):e18416. PubMed ID: 31861007
[TBL] [Abstract][Full Text] [Related]
26. THE RELATIONSHIP OF BRAF
Santhanam P; Khthir R; Solnes LB; Ladenson PW
Endocr Pract; 2018 Jan; 24(1):21-26. PubMed ID: 29144823
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
[TBL] [Abstract][Full Text] [Related]
28. Does V600E BRAF mutation predict vinorelbine efficacy? A proof-of-concept from a lung micropapillary adenocarcinoma metastatic to the breast.
Carassai P; Jocollé G; Donati G; Spinazzé S; Baiocco C; Baderna P; Martinet A; Lococo F; Migliaccio F; Rossi G
Pathologica; 2017 Dec; 109(4):426-428. PubMed ID: 29449740
[No Abstract] [Full Text] [Related]
29. Pulmonary sclerosing pneumocytoma containing spindle cells with sarcomatoid features: a case report with literature review.
Liang J; Du Q; Ye X; Huang W
Diagn Pathol; 2023 Feb; 18(1):16. PubMed ID: 36759857
[TBL] [Abstract][Full Text] [Related]
30. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
[TBL] [Abstract][Full Text] [Related]
31. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
32. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma.
Scortegagna M; Ruller C; Feng Y; Lazova R; Kluger H; Li JL; De SK; Rickert R; Pellecchia M; Bosenberg M; Ronai ZA
Oncogene; 2014 Aug; 33(34):4330-9. PubMed ID: 24037523
[TBL] [Abstract][Full Text] [Related]
33. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H
Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
[TBL] [Abstract][Full Text] [Related]
34. The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis.
Barbaro D; Incensati RM; Materazzi G; Boni G; Grosso M; Panicucci E; Lapi P; Pasquini C; Miccoli P
Endocrine; 2014 Apr; 45(3):462-8. PubMed ID: 23925579
[TBL] [Abstract][Full Text] [Related]
35. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
[TBL] [Abstract][Full Text] [Related]
36. Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.
Trejo CL; Green S; Marsh V; Collisson EA; Iezza G; Phillips WA; McMahon M
Cancer Res; 2013 Nov; 73(21):6448-61. PubMed ID: 24019382
[TBL] [Abstract][Full Text] [Related]
37. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract][Full Text] [Related]
38. Single Point Mutations in Pediatric Differentiated Thyroid Cancer.
Alzahrani AS; Murugan AK; Qasem E; Alswailem M; Al-Hindi H; Shi Y
Thyroid; 2017 Feb; 27(2):189-196. PubMed ID: 27824297
[TBL] [Abstract][Full Text] [Related]
39. The Association of the BRAF-V600E Mutation with the Expression of the Molecular Markers in the Primary Tumor and Metastatic Tissue in Papillary Thyroid Cancer.
Spirina LV; Chizhevskaya SY; Kovaleva IV; Kondakova IV
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2017-2024. PubMed ID: 34319022
[TBL] [Abstract][Full Text] [Related]
40. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]